← Back to Search

Tyrosine Kinase Inhibitor

Sunitinib for Pheochromocytoma (SNIPP Trial)

Phase 2
Waitlist Available
Led By Jennifer Knox, MD, FRCPC
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Life expectancy of greater than 24 weeks.
Histologically or cytologically confirmed diagnosis of malignant paraganglioma or pheochromocytoma and either evidence of metastases or unresectability.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up patient specific based on disease progression
Awards & highlights

SNIPP Trial Summary

This is an open-label phase II study of an investigational drug, sunitinib malate in patients with advanced malignant paraganglioma or phaeochromocytoma cancer. Paragangliomas (PGs) are tumours that arise from the para-sympathetic system in the head and neck and sympathetic system in the thorax and abdomen. Paragangliomas that secrete hormones (catecholamines) from the adrenal glands are called pheochromocytomas (PCs). In this study, patients whose disease has advanced or spread despite prior standard therapy, will receive sunitinib for 4-weeks followed by a 2-week rest period, for up to 12 months, in the absence of disease progression. Sunitinib is an investigational drug, which has been shown to shrink tumours in several tumour models. The study will evaluate the efficacy as well as the toxicity profile of sunitinib when used as an alternative treatment for patients with PG/PC tumours.

Eligible Conditions
  • Pheochromocytoma
  • Paraganglioma

SNIPP Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

SNIPP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 12 weeks (2 cycles)
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 12 weeks (2 cycles) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinical benefit rate (CBR) which is defined as either a partial response (PR) complete response (CR) or stable disease (SD) for ≥ 12 weeks measured using Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
Secondary outcome measures
Biochemical response of > 20% drop in; 24-hour urinary metanephrines, catecholamines or serum chromogranin A, sustained for > 12-week period
Overall response rate (PR) + (CR)
Overall survival
+1 more

Side effects data

From 2019 Phase 2 trial • 305 Patients • NCT01984242
46%
Proteinuria
41%
Fatigue
37%
Arthralgia
30%
Cough
30%
Nausea
28%
Diarrhoea
28%
Epistaxis
26%
Rash
26%
Hypertension
22%
Abdominal pain
22%
Blood creatinine increased
20%
Musculoskeletal pain
20%
Pain in extremity
20%
Constipation
20%
Dysphonia
17%
Oedema peripheral
17%
Pruritus
17%
Upper respiratory tract infection
17%
Back pain
17%
Hypothyroidism
17%
Dyspnoea
15%
Headache
13%
Stomatitis
13%
Vomiting
13%
Mucosal inflammation
13%
Oropharyngeal pain
13%
Pyrexia
11%
Abdominal distension
11%
Hyperglycaemia
11%
Hyponatraemia
11%
Productive cough
11%
Dry mouth
11%
Nasal congestion
11%
Dry skin
9%
Haematuria
9%
Dizziness
9%
Chest pain
9%
Sinusitis
9%
Hypophosphataemia
9%
Hyperkalaemia
9%
Muscle spasms
9%
Night sweats
9%
Decreased appetite
7%
Flank pain
7%
Adrenal insufficiency
7%
Gingival bleeding
7%
Myalgia
7%
Neck pain
7%
Dyspepsia
7%
Blood lactate dehydrogenase increased
7%
Dehydration
7%
Hypoalbuminaemia
7%
Insomnia
7%
Acute kidney injury
7%
Nocturia
7%
Dyspnoea exertional
7%
Rhinorrhoea
7%
Haemorrhoids
7%
Pneumonia
7%
Tumour pain
7%
Rash erythematous
7%
Ecchymosis
7%
Platelet count decreased
7%
Protein total increased
7%
Contusion
7%
Dry eye
4%
Thrombocytopenia
4%
Anaemia
4%
Hypomagnesaemia
4%
Depression
4%
Weight decreased
2%
Pancreatitis acute
2%
Appendicitis
2%
Asthenia
2%
Bronchitis
2%
Muscle haemorrhage
2%
Limb Operation
2%
Embolism
2%
Hypertensive crisis
2%
Oedema
2%
Sepsis
2%
Femur fracture
2%
Paraesthesia
2%
Cardiomyopathy
2%
Urinary tract infection
2%
Diverticulitis
2%
Atrial fibrillation
2%
Anxiety
100%
80%
60%
40%
20%
0%
Study treatment Arm
Atezolizumab (Crossover)
Atezolizumab and Bevacizumab
Atezolizumab
Sunitinib
Sunitinib (Crossover)

SNIPP Trial Design

1Treatment groups
Experimental Treatment
Group I: Open label - SunitinibExperimental Treatment1 Intervention
Sunitinib, 50mg daily, once daily for 4 weeks followed by a 2-week break
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sunitinib
2014
Completed Phase 3
~4380

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,456 Previous Clinical Trials
482,774 Total Patients Enrolled
PfizerIndustry Sponsor
4,556 Previous Clinical Trials
10,907,658 Total Patients Enrolled
1 Trials studying Pheochromocytoma
25 Patients Enrolled for Pheochromocytoma
Jennifer Knox, MD, FRCPCPrincipal InvestigatorThe Princess Margaret Cancer Foundation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~2 spots leftby Mar 2025